Tibetan Medicine Liuwei Dingxiang Pills Decoction Inhibits Pseudomonas aeruginosa via Fatty Acid Metabolic Reprogramming and Lipid Peroxidation Revealed by Untargeted Metabolomics Authors: Ping He, Ling Yi, Shuyao Ren, Zhen Ci, Cuomu Yixi, Xiaokang Hao, Yanli Zhang, Xiaoxing Liu, Xiaoli Zhu, Datao Lin, Jehangir Khan, Caixia Wu Published: 2026 ABSTRACT AbstractBackgroundPseudomonas aeruginosa is a major opportunistic pathogen and poses threat to public health. Traditional medicines are a valuable source of novel antibacterial agents. Liuwei Dingxiang Pills, a classical Tibetan formulation, have demonstrated clinical efficacy, but the antibacterial mechanisms remain unclear. This study evaluated the antibacterial effect and mechanism against P. aeruginosa via untargeted metabolomics.MethodsMinimum inhibitory concentration (MIC) were determined using agar diffusion and broth microdilution methods. Bacterial growth curves were plotted for different concentrations. Chemical constituents of the decoction and the bacterial metabolic profiles during the logarithmic phase were analyzed using high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS). Differential metabolites were annotated and assessed through KEGG (Kyoto Encyclopedia of Genes and Genomes) enrichment analysis.ResultsThe decoction contained multiple bioactive compounds including gallic acid, homoorientin, corilagine, isovitexin, swertiamarin, isoalantolactone, coumarin, etc. It significantly inhibited all nine tested P. aeruginosa strains, with inhibition zones positively correlated with drug concentration. The MIC was 50 mg/mL. Untargeted metabolomics after sub-MIC treatment identified 346 differential metabolites (p < 0.05), 281 were upregulated and 65 were downregulated. Notably, the oxidation products of linoleic acid (8-HPODE, 9/13-HODE, 9/13-OxoODE) and other derivatives 9,10-DHOME, 12,13-DHOME and γ-linolenic acid were significantly increased. Additionally, alpha-linolenic acid and traumatin in the α-linolenic acid pathway were also elevated. KEGG analysis indicated the activation of linolenic acid and α-linolenic acid metabolic pathways, suggesting that unsaturated fatty acid metabolism is the primary target of antibacterial action.ConclusionMetabolomics analysis indicated that Liuwei Dingxiang Pills exert antibacterial effects through a mechanism involving multiple components and targets, synergistically inducing membrane disruption and endogenous oxidative stress, thereby triggering extensive linoleic acid-centered lipid peroxidation and metabolic reprogramming in P. aeruginosa. This novel mechanism provides theoretical basis for development of new antibacterial strategies targeting bacterial lipid metabolism.Keywords: Liuwei Dingxiang pills, Pseudomonas aeruginosa, antibacterial mechanism, metabolomics, lipid peroxidation Background The rising prevalence of multidrug-resistant (MDR) bacterial infections is a serious global public health concern.1 Pseudomonas aeruginosa is a major nosocomial pathogen due to its environmental adaptability, drug resistance, and biofilm formation, particularly in immunocompromised and critically ill patients.2 It causes both acute and chronic infections, including those associated with cancer-related trauma, cystic fibrosis, chronic obstructive pulmonary disease, and ventilator-associated pneumonia.3 The efficacy of existing antibiotics is declining, highlighting the urgent need for new antibacterial compounds and mechanistic insights.4 Traditional medicine (TM) has a long history and rich experience in anti-infective therapy, offering valuable leads for new antibacterial drug discovery.5,6 Its global influence has increased, with more countries recognizing and exploring TM’s therapeutic potential.6 Recently, metabolomics has emerged as a high-throughput tool for studying the antibacterial mechanisms of TM.7–9 Liuwei Dingxiang Pills are a classic Tibetan formulation with dingxiang as the main ingredient, supplemented with five other herbs. Clinically, they are used to treat “clear heat, detoxify, and relieve sore throat and swelling”, particularly for upper respiratory tract infections such as pharyngitis. Therefore, several bacteria related to respiratory tract infections (Staphylococcus aureus, Streptococcus pyogenes, Klebsiella pneumoniae, S. pneumoniae) and other common clinical bacteria (Escherichia coli, P. aeruginosa, Salmonella, Enterococcus, etc). By chance, we found that this medicine had a significant antibacterial effect on S. aureus and P. aeruginosa. However, no systematic studies have investigated the antibacterial activity and mechanisms against P. aeruginosa according to PubMed and Web of Science. This study demonstrates that the Liuwei Dingxiang Pills decoction exhibits significant in vitro antibacterial activity against P. aeruginosa ATCC27853 and clinical strains. By integrating chemical analysis, microbiological assays, and untargeted metabolomics, we identified active compounds and revealed their impact on bacterial metabolic networks. Notably, the decoction induces a “lipid peroxidation metabolic waterfall” driven by oxidative stress, with linoleic acid metabolism as the core, providing a mechanistic basis for the multi-component, multi-target synergistic effects of Tibetan medicine. Materials and Methods Decoction Preparation and Ingredient Identification Liuwei Dingxiang Pills (Batch Number: 20210701) were purchased from the Tibetan God Monkey Hospital in 2024 (Figure 1A). The pills were ground into powder, 10 g of powder was pre-soaked in 120 mL ultrapure water for 1 h in a 200 mL beaker and then decocted over low heat for approximately 2 h. After cooling to room temperature, the decoction was centrifuged at 8000 rpm for 10 min, and the supernatant was collected. The residue was decocted twice: first with 60 mL of water for 1 h and then with 30 mL for 30 min. The supernatant was collected, combined, concentrated to approximately 1000 mg/mL, subpackaged in sterile tubes, and stored at 4 °C. Ingredient identification was performed by Shanghai Fuda Detection Technology Company using HPLC-MS/MS. The drug information and inhibitory zones. Drug instruction (A) and antibacterial effect by agar perforation method (B). Bacterial Strains and Culture Conditions Clinical isolates were provided by the laboratory departments both of Central Hospital of Xianyang and the Affiliated Hospital of Xizang Minzu University. 6 were sensitive strains and 3 were multidrug-resistant strains (mainly resistant to piperacillin/tazobactam, ceftazidime, cefepime, cefoperazone/sulbactam, aztreonam and levofloxacin). Pure culture of bacteria rather than human specimens were used in antibacterial experiments. The P. aeruginosa ATCC 27853 strain was used for antibacterial mechanism and metabolomic experiments. Mueller-Hinton (MH) broth and MH agar medium were used for bacterial culture. Instruments and Reagents Key instruments included: clean bench (BBS-DDC, Shandong Boke Disinfection Equipment Co., Ltd.), incubator (MJ-150-1, Shanghai Yiheng Scientific Instrument Co., Ltd.), electronic balance (JA2003N, Shanghai Youke Instrument and Meter Co., Ltd.), high-speed refrigerated centrifuge (HC-3016R, Anhui Zhongke Zhongjia Scientific Instrument Co., Ltd.), high-pressure steam sterilizer (BKQ-B100, Shandong Boke Disinfection Equipment Co., Ltd.), spectrophotometer (Nanodrop 2000, Thermo Fisher Scientific), water purification system (Millipore Milli-Q Direct 8), microplate reader (Multiskan GO, Thermo Fisher Scientific), constant-temperature shaker (THZ-100, Shanghai Yiheng Scientific Instrument Co., Ltd.), and turbidimetric tube (Hunan Bikerman Holding Co., Ltd.). The MH medium was purchased from Zhongshan Baiwei Microbial Technology Co. Antibacterial Activity Analysis Agar Diffusion Method Nine P. aeruginosa strains were inoculated separately onto MH agar at 37 °C. Bacterial suspensions were adjusted (saline) to 0.5 McFarland, and six wells (6.4 mm diameter) were made per plate (90 mm diameter). 200 μL bacterial suspension was spread on the MH plate, and 100 μL decoction was added to each well at concentrations of 800, 250, and 50 mg/mL. An antibiotic susceptibility paper was used as a control (Figure 1B). After 24 h incubation, the diameters of the inhibition zones were measured using a vernier caliper. For each group, experiments were performed in triplicate, and the averages were calculated. Minimum Inhibitory Concentration (MIC) Detection MIC was determined by broth microdilution with minor modifications.10,11 The decoction was initially diluted to 200 mg/mL and then serially diluted two-fold with P. aeruginosa ATCC 27853 suspension to obtain 100, 50, 25, and 12.5 mg/mL test concentrations. In detail, the bacterial suspension (0.5 McFarland turbidity) was first diluted 100 times with MH broth, and 100 μL was transferred to a 96-well plate. Then, 100 μL of the test decoction was mixed in a 96-well plate. Negative and positive controls were sterile media with/without bacteria. After incubation at 37 °C for 24 h, MIC was defined as the lowest concentration with no visible turbidity. Experiments were performed in triplicate. Growth Curve Assay Bacterial growth curves were plotted at 1/8MIC, 1/4MIC, 1/2MIC, and MIC. Decoction (1000 mg/mL) was diluted with sterile MH broth. Briefly, 20 mL culture medium containing decoction at different concentrations was added to 100 mL flasks, and then 200 μL bacterial suspension (0.5 McFarland Turbidity) was mixed into each flask, which was incubated at 37 °C for 48 h with shaking at 120 rpm. The OD600 was measured at 0, 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, and 48 h. MH broth with bacteria was used as the control group. The experiments were performed in triplicate. Sample Preparation for Metabolomics Based on the MIC and growth curve results, bacterial cells in the middle logarithmic growth phase were harvested under 1/2 MIC dose treatment. The cells were centrifuged at 12,000 g for 8 min at 4 °C and metabolism was quenched immediately. Untreated cultures were used as controls. The metabolites were analyzed using UHPLC-MS/MS. Metabolomics Analysis The raw data underwent processing, integrity checks, filtering, and normalization. XCMS software extracted and aligned ion peaks, and the metabolites were identified using an in-house secondary mass spectrometry library. The HMDB (https://hmdb.ca/) and PubChem (https://pubchem.ncbi.nlm.nih.gov/) databases were used for the annotation. Differential metabolites were analyzed by PLS-DA, with thresholds |log2 (fold change)| > 1.2 and p < 0.05. Volcano plots and heat maps visualized changes, and KEGG enrichment analysis clarified the potential antibacterial mechanisms. Data Analysis Data were expressed as mean ± SD (standard deviation), and analyzed using GraphPad Prism version 9.0 (GraphPad Software, San Diego, CA, USA), and one-way ANOVA in SPSS version 26.0 (IBM Corp., Armonk, NY, USA). Statistical significance was set at p < 0.05. Results Decoction Ingredient Identification HPLC-MS/MS analysis of the Liuwei Dingxiang Pills decoction revealed approximately 100 compounds, primarily flavonoids and phenolic acids. The top 20 active ingredients were gallic acid, quinic acid, homoorientin, corilagine, isovitexin, ellagic acid, swertiamarin, shikimic acid, etc (Table 1). Many of these compounds have documented antibacterial activities. Detailed information is provided in Supplementary File 1. Table 1Top 20 Compounds Identified in Decoction by HPLC/MSCompound NameFormulaMWRT (min)Peak %Gallic acidC7H6O51703.37227.593PyrogallolC6H6O31263.3849.908Quinic acidC7 H12O61921.3944.829HomoorientinC21H20O1144819.0524.738CorilaginC27H22O1863418.1524.682IsovitexinC21H20O1043220.0094.481Liguiritigenin-7-O-β-D-apiosyl-4’-O-β-D-glucosideC26H30O1355020.1493.764IsoliquiritigeninC15H12O425620.1553.026Ellagic acidC14H6O830219.8622.7522-Pyrrolidinecarboxylic acidC5H9NO21151.4192.726Diammonium glycyrrhizinateC42H62O1682229.9122.697Loganic acidC16H24O1037616.5862.267Citric acidC6H8O71921.4411.720Glycyrrhizic acidC42H62O1682228.6421.6304-MethylumbelliferoneC10H8O317617.6341.415SwertiamarinC16H22O1037417.6421.346Shikimic acidC7H10O51741.8471.175FormononetinC16H12O426827.7071.169Brevifolincarboxylic acidC13H8O829217.3051.108Methyl gallateC8H8O518415.7801.069 Top 20 Compounds Identified in Decoction by HPLC/MS Antibacterial Activity Detection of Inhibition Zone Diameter and MIC Liuwei Dingxiang Pills inhibited all nine P. aeruginosa strains, and the inhibition zones were positively correlated with the decoction concentration (Table 2). The MIC against P. aeruginosa ATCC27853 was 50 mg/mL, confirming its significant antibacterial activity. Table 2Antibacterial Effect of Decoction on P. aeruginosaBacterial StrainDecoction Concentration Gradient800 mg/mL250 mg/mL50 mg/mLP.a ATCC2785318.30±0.69a13.03±0.39b−P.a isolated_117.70±0.87a12.80±0.12b−P.a isolated_215.10±0.81a12.85±0.26b−P.a isolated_317.18±0.62a13.33±0.62b−P.a isolated_415.73±1.07a12.50±0.99a−P.a isolated_518.65±0.55a17.10±0.29a7.33±0.33bP.a isolated_611.45±0.55−−P.a isolated_710.80±2.19−−P.a isolated_812.15±0.38−−Notes: Different letters (a/b) in the same row indicate significant differences between different concentration groups (p < 0.05). “−” indicates no antibacterial effect. Antibacterial Effect of Decoction on P. aeruginosa Notes: Different letters (a/b) in the same row indicate significant differences between different concentration groups (p < 0.05). “−” indicates no antibacterial effect. Growth Curve Inhibition Treatment with the MIC (50 mg/mL) significantly inhibited ATCC27853 growth (Figure 2). The OD600 values in the treated group were consistently lower than those of the control group. Decoction at 50 mg/mL exhibited sustained inhibition over 48 h. Inhibitory effect on the growth curve of P. aeruginosa ATCC27853. Metabolomics Analysis General Untargeted Metabolomics HPLC-MS/MS identified 1014 metabolites, of which 346 were significantly altered (p < 0.05), 281 were upregulated, and 65 were downregulated (Figure 3C and Supplementary File 2). Pearson’s correlation coefficients indicated good within-group reproducibility (Figure 3A). PLS-DA clearly separated the control and decoction-treated groups, demonstrating pronounced metabolomic changes (Figure 3B). Volcano maps highlighted differential metabolites, with upregulated compounds in red, downregulated in blue, and unchanged in gray (Figure 3C). Sample quality control analysis and differential metabolites analysis. (A) Pearson correlation analysis was performed on the abundance values of quality control samples. (B) Differential metabolites were analyzed using the multivariate statistical method PLS-DA. (C) The overall distribution of differential metabolites is shown in volcano plots. KEGG Enrichment Analysis KEGG enrichment analysis revealed that most differential metabolites were associated with linoleic acid metabolism, α-linolenic acid metabolism, and phenylpropanoid/flavonoid metabolism (Figure 4). Most phenylpropanoid/flavonoid metabolites corresponded to the decoction ingredients (Supplementary File 1), confirming that lipid metabolism, especially unsaturated fatty acids, is the core target. KEGG enrichment analysis of significantly differential metabolites. Systematic Activation of Linoleic Acid Metabolic Network Detailed analysis showed marked activation of the linoleic acid pathway (Figure 5). The linoleic acid level increased significantly by 7.5 times in the upstream substrate. Its lipoxygenase/oxidation products increased sharply, including 9-HPODE (5.6 times), 13-HODE (21.0 times), 8-HPODE (4.3 times), as well as the ultimate oxidation products 9-OxoODE (21.6 times) and 13-OxoODE (13.2 times). The downstream epoxy/diol derivatives also increased simultaneously, such as 12, 13-EpOME (49.1 times), 12, 13-DHOME (27.4 times) and 9, 10-DHOME (30.4 times). Additionally, the level of gamma-linolenic acid in this pathway increased 36.1 times, which is also related to arachidonic acid metabolism. The differential metabolites related to the linoleic acid metabolic pathway. Brown circles indicated differential metabolites in this pathway. Changes in Alpha-Linolenic Acid Pathway Alpha-linolenic acid metabolites were upregulated, although less dramatically than linoleic acid (Figure 6). The levels of the four metabolites in this pathway also increased simultaneously, including the upstream substrates alpha linolenic acid (by 49.8 times) and the downstream derivatives stearidonic acid (4.5 times), traumarin (12.5 times) and 3-Hexenyl acetate (6.3 times). The differential metabolites related to the α-linolenic acid metabolic pathway. Brown circles indicated differential metabolites in this pathway. Discussion P. aeruginosa is a major opportunistic pathogen that causes severe infections in immunocompromised patients.12 This study systematically elucidates a novel antibacterial mechanism of Liuwei Dingxiang Pills, demonstrating the disruption of bacterial lipid metabolic homeostasis, with linoleic acid peroxidation at its core. Linoleic acid, a plant-derived unsaturated fatty acid, exhibits antibacterial activity against P. aeruginosa,13 Escherichia coli,14 and Staphylococcus aureus.15 Previous studies have identified linoleic acid as a differential metabolite in antibacterial treatments,7,16–18 but its metabolic pathway has not been previously recognized as a key antibacterial mechanism.19 The antibacterial effect of Liuwei Dingxiang Pills is primarily mediated through the synergistic action of its active compounds, including polyphenols (gallic acid,20–22 ellagic acid,23 corilagin), saponin (glycyrrhizic acid24), and coumarin.25 These compounds act via dual mechanisms. They destabilize the bacterial membrane phospholipid bilayer, increasing permeability and causing leakage of intracellular contents. Concurrently, polyphenols and other pro-oxidant components induce endogenous oxidative stress by generating reactive oxygen species (ROS) redox cycles,26 triggering a lipid peroxidation cascade (“metabolic waterfall”) that produces oxylipins and lipoperoxides (Figure 5). This synergy not only establishes a highly oxidizing intracellular environment, but also renders membrane lipids, particularly linoleyl groups, which are more susceptible to oxidative damage, amplifying bacterial metabolic stress and dysfunction. KEGG enrichment analysis indicated that lipid metabolism, particularly the linoleic and alpha-linolenic acid metabolic pathways, was the core target of the decoction action (Figures 5 and 6). Notably, P. aeruginosa cannot synthesize linoleic acid endogenously, and membrane-associated linoleic acid is acquired from environmental uptake.27 We propose that the combined effects of oxidative stress and membrane disruption activate bacterial damage-response mechanisms, such as phospholipase-mediated hydrolysis, which releases free linoleic acid from membrane phospholipids (e.g, phosphatidylethanolamine).28 Liberated linoleic acid undergoes rapid enzymatic oxidation via lipoxygenases29,30 and non-enzymatic peroxidation in ROS-rich environments, forming hydroperoxides (HPODEs), hydroxyl derivatives (HODEs), and highly reactive carbonyl products (OxoODEs). Partial linoleic acid is also metabolized by CYP epoxygenases into EpOMEs and DHOMEs. Although the antibacterial properties of linoleic acid are well documented,31 the contribution of its oxidation products to bacterial inhibition remains underexplored. Some oxidized lipids are further cleaved into small molecules, such as traumatin, which may interfere with bacterial stress responses, further amplifying antibacterial efficacy. While this study provides novel mechanistic insight into the antibacterial action of Liuwei Dingxiang Pills against Pseudomonas aeruginosa, several limitations warrant consideration. First, our experiments were conducted in vitro under controlled culture conditions, which do not entirely mimic the complex nutrient, immune, and microbial interactions present in vivo. Second, although untargeted metabolomics offers broad metabolic coverage, some identified features remain putatively annotated, and definitive structural validation of all lipid species, especially oxidized derivatives, has not been performed. Third, the proposed mechanism of ROS induction was inferred from metabolic alterations and not directly measured; direct biochemical assays for reactive oxygen species would strengthen causal interpretations. Finally, while linoleic acid peroxidation has emerged as central, functional assays confirming the antibacterial potency of key oxidized lipids are needed to fully validate their roles. These limitations, which are common to metabolomics and mechanistic antibacterial studies, should guide future investigations to refine and extend our findings. Conclusion This study systematically revealed the antibacterial mechanism of the traditional Tibetan medicine Liuwei Dingxiang Pills against Pseudomonas aeruginosa through an integrated approach combining microbiology, chemical analysis, and untargeted metabolomics. The decoction exerts its effect via the synergistic action of multiple active components, including pro-oxidants and membrane-disrupting compounds, which collectively induce endogenous oxidative stress and trigger extensive lipid peroxidation centered on linoleic acid derived from membrane phospholipids. This cascade not only generates cytotoxic oxidized lipids, but also destabilizes the overall bacterial metabolic network, representing a novel metabolic reprogramming-based antibacterial strategy distinct from conventional antibiotics. These findings provide a mechanistic basis for the development of new antibacterial agents or adjuvants targeting bacterial lipid metabolism. Future research will focus on validating the direct toxicity of key oxidized lipids, assessing their effects on bacterial virulence traits, such as biofilm formation, and optimizing combinations of active components for enhanced therapeutic efficacy. Funding Statement This work was supported by Project of the Tibet Natural Science Foundation (No. XZ202401ZR0017 and XZ202401ZR0043), the Research Project of Xizang Minzu University (No. 25MDY11), the National Natural Science Foundation of China (82202560 and 82272361), and the Youth S&T Talent Support Program of Guangdong Provincial Association for Science and Technology (SKXRC2025159). Abbreviations DMs, Differential metabolites; MIC, Minimum Inhibitory Concentration; ROS, Reactive oxygen species; SD, Standard deviation; TM, Traditional medicine. Data Sharing Statement The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request. Ethics Approval This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Xizang Minzu University (No. 2025-081). Bacterial isolation and culture were routinely carried out in laboratory department and all individual patient information was removed before research, the Ethics Committee of Xizang Minzu University waived the requirement for informed consent from individual patients. Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval ofthe version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this study. References Associated Data Data Availability Statement The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.